← Leaderboards
Haiyan Fu
University Of North Carolina Chapel Hill
$5,284,175
Attributed
$7,985,187
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,985,187 · 8
By mechanism
U01$4,349,431 · 1
R41$1,734,841 · 3
R01$1,045,665 · 2
R21$855,250 · 2
Top collaborators
- Kevin M Flanigan5 shared
- Douglas M Mccarty3 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Tal Kafri$11,523,888
- Douglas M McCarty$10,391,159
- Kunihiko Suzuki$629,679
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorDoseGene DeliveryClinical ApplicationTranslationsLysosomal Storage DiseasesEnzymesRegimenChildRecombinant Adeno-Associated Virus (Raav)FamilyAdeno-Associated Viral VectorMucopolysaccharidosesSafetyExperimental StudyGene ExpressionNeurogeneticsMouse ModelComplementary DnaCellsDefectMediatingToxic Effect
Grant awards (19)
Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC$349,909
R41 · FY2025 · NS · contact PI
Develop AAV9 gene replacement therapy for treating MPS I$323,802
R41 · FY2023 · NS · contact PI
Develop AAV9 gene replacement therapy for treating MPS I$378,882
R41 · FY2022 · NS · contact PI
Development of gene therapy product for treating MPS IIIB$284,425
R41 · FY2021 · NS · contact PI
Facilitate by-stander effects by EV-mRNA cargo in AAV gene therapy for MPS IIIC$427,625
R21 · FY2020 · NS · contact PI
Development of gene therapy product for treating MPS IIIB$397,823
R41 · FY2020 · NS · contact PI
Rapid Transient Depletion of Pre-existing Antibodies for rAAV Gene Delivery$194,375
R21 · FY2020 · AI · contact PI
Rapid Transient Depletion of Pre-existing Antibodies for rAAV Gene Delivery$233,250
R21 · FY2019 · AI · contact PI
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL$262,382
R01 · FY2017 · CA · contact PI
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL$41,606
R01 · FY2017 · CA · contact PI
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$1,204,789
U01 · FY2014 · NS · contact PI
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$1,207,188
U01 · FY2013 · NS · contact PI
Treating the CNS and Somatic Diseases of MPS IIIB by Systemic Gene Delivery$167,871
U01 · FY2013 · NS · contact PI
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$879,620
U01 · FY2012 · NS · contact PI
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$889,963
U01 · FY2011 · NS · contact PI
CNS Gene Therapy for Mucopolysaccharidosis IIIB w/ AAV$170,400
R01 · FY2004 · DK
CNS Gene Therapy for Mucopolysaccharidosis IIIB w/ AAV$64,302
R01 · FY2004 · DK
CNS Gene Therapy for Mucopolysaccharidosis IIIB w/ AAV$254,625
R01 · FY2003 · DK
CNS Gene Therapy for Mucopolysaccharidosis IIIB w/ AAV$252,350
R01 · FY2002 · DK